CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $15.1111.

CYRX has been the subject of a number of recent research reports. Needham & Company LLC upped their target price on CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. KeyCorp upped their target price on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings raised shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Finally, Guggenheim lifted their price objective on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, May 5th.

Get CryoPort alerts:

View Our Latest Stock Report on CryoPort

Insider Buying and Selling

In other CryoPort news, Director Ramkumar Mandalam sold 23,214 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $15.44, for a total transaction of $358,424.16. Following the completion of the transaction, the director directly owned 67,894 shares in the company, valued at $1,048,283.36. This represents a 25.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark W. Sawicki sold 3,235 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $25,880.00. Following the transaction, the insider owned 103,697 shares of the company’s stock, valued at $829,576. This represents a 3.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 213,880 shares of company stock valued at $3,285,873. 10.00% of the stock is owned by insiders.

Institutional Trading of CryoPort

Large investors have recently made changes to their positions in the business. Basepoint Wealth LLC bought a new stake in shares of CryoPort during the fourth quarter worth $34,000. Tower Research Capital LLC TRC grew its holdings in shares of CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after purchasing an additional 4,375 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of CryoPort during the third quarter worth $79,000. Quadrature Capital Ltd bought a new stake in shares of CryoPort during the fourth quarter worth $97,000. Finally, Corient Private Wealth LLC bought a new stake in shares of CryoPort during the fourth quarter worth $113,000. Institutional investors own 92.90% of the company’s stock.

CryoPort Stock Performance

Shares of CYRX opened at $14.77 on Friday. The company has a 50-day simple moving average of $12.18 and a 200-day simple moving average of $10.26. The firm has a market capitalization of $744.44 million, a P/E ratio of 10.94 and a beta of 1.90. CryoPort has a 52 week low of $6.16 and a 52 week high of $16.73.

CryoPort (NASDAQ:CYRX – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The company had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. As a group, equities analysts forecast that CryoPort will post -0.85 earnings per share for the current year.

CryoPort Company Profile

(Get Free Report)

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

Featured Stories

• Five stocks we like better than CryoPort
• Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
• This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
• Intel Is the Market’s Most Mispriced AI Hedge
• The Biggest Opportunity From SpaceX’s IPO May Surprise You

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.